Key facts
- This page summarizes Robert Iannone's Form 4 filing for Jounce Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2022, 21:05.
Robert Iannone - 24 Jun 2022 Form 4 Insider Report for Jounce Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2022, 21:05:21 UTC
- Prior SEC filing
- 10 Jun 2022
- Next SEC filing
- 13 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Caroline Gammill, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Iannone filed Form 4 for Jounce Therapeutics, Inc. on 28 Jun 2022.
Change
- Previous filing in this sequence was filed on 10 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JNCE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 24 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $2.80
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.